Meglumine antimoniate
QP51DX01 (WHO ) | |
Identifiers | |
---|---|
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Meglumine antimoniate is a medicine used to treat leishmaniasis.[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[1] It is given by injection into a muscle or into the area infected.[1]
Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain,
kidney problems.[1] It should not be used in people with significant heart, liver, or kidney problems.[1] It is not recommended during breastfeeding.[1] It belongs to a group of medications known as the pentavalent antimonials.[1]
Meglumine antimoniate came into medical use in 1946.[2] It is on the World Health Organization's List of Essential Medicines.[3] It is available in Southern Europe and Latin America but not the United States.[4][5]
Society and culture
It is manufactured by
.See also
References
- ^ ISBN 9789241547659.
- ISBN 9780470015520. Archivedfrom the original on 2016-12-20.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ISBN 978-1437735727. Archivedfrom the original on 2016-12-20.
- ISBN 9780781733717. Archivedfrom the original on 2016-12-20.
- ^ "Sanofi-Aventis Bekräftigt Seine Verpflichtung Zur Sicherstellung Des Zugangs Zu Medikamenten in Den "Südlichen Ländern" Mit Einer Politik Der Gestaffelten Arzneimittelpreise Je Nach Bevölkerungseinkommen" [Sanofi-Aventis Reaffirms Its Commitment to Ensuring Access to Medicines in the "Southern Countries" With a Policy of Tiered Drug Prices Depending on Population Income]. Aventis press release (in German). 15 April 2005. Archived from the original on 22 May 2014.